# Post-Marketing Surveillance of Prazaxa® on the Long-term Use in Patients With Nonvalvular Atrial Fibrillation

> **NCT01491178** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 6772 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Prazaxa

## Key facts

- **NCT ID:** NCT01491178
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12-12
- **Primary completion:** 2016-08-02
- **Final completion:** 2016-08-02
- **Target enrollment:** 6772 (ACTUAL)
- **Last updated:** 2018-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01491178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01491178, "Post-Marketing Surveillance of Prazaxa® on the Long-term Use in Patients With Nonvalvular Atrial Fibrillation". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01491178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*